Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Likewise- above excitement now...
Worth a read. 'Preparing for a challenging winter 2020/2021' report dated 14th July 2020 gives a stark view as to what we have unfortunately probably got coming down track this Autumn / Winter. The view on rapid testing and effective treatments are included in pages 36 & 37. Speed and accuracy are essential. ODX testing capability 'roll out' is an urgent and absolute must.
What is going on here - sit tight or bail out? Advice please............
Good morning all,
UK investor sentiment here has seemingly temporarily evaporated from COVID-19 plays potentially because of a perceived improving current UK and European infection position. UK based technology and research initiatives such as SNG (plus others) fundamentally have a worldwide application and significant value and remains particularly critical to fighting a global pandemic, which is actually still raging in South America particularly, and unfortunately more than likely to reappear close to home in the future. Pharma players operate on a global production and product supply basis, and will engage in M&A on that basis particularly for attractive UK based companies such as SNG if trials are deemed successful. Therefore my view is that the decline in demand, and recent drop in share value, is both premature and over stated.Fingers crossed.
Absolutely fantastic - I listened to the Radio 4 interview, for positive about the 20 second test and optimistic as to the positive impact it will have on track / test / trace key government policy. So frustrating when the interviewers don't ask the follow up questions to find out more about the 20 second results test!!!!!!!!!!
Adding interferon-beta to a ****tail of the antiviral drugs lopinavir, ritonavir and ribavirin helped alleviate symptoms and shorten the duration of viral shedding (contagion) and hospital stays of mildly or moderately ill COVID-19 patients, according to results of a small randomized trial conducted at six hospitals in Hong Kong. The time it took for at least half the patients to have negative coronavirus tests was seven days with add-on interferon, compared to 12 days without it, researchers reported on Sunday in The Lancet. Overall, 86 patients received the interferon-containing combination and 41 got the antivirals without interferon. When the study started, half the patients had already been symptomatic for more than five days. The combination that included interferon "also alleviated symptoms completely within four days - a significantly shorter time than the control," researchers said, adding that a larger trial to confirm these results is needed. (bit.ly/3dBLd96;bit.ly/3dBpPAJ)
UK coronavirus study reassures pregnant women; Swedish study says don't downplay risks
Just like AAOG.............
The patient interviewed from Leicester Royal Infirmary hails from Melton Mowbray, local guy - sounds extremely likely that he was treated with SNG-001 as it is quoted as being one of the trial drugs at Leicester currently, and my view is that the method of treatment application almost points it towards SNG-001
Good afternoon The tone from Sky news today is very much about the increasing requirement for effective treatments for CV-19 and the lack
of global cooperation to deliver them in the shortest period of time possible. There is an incredible global demand for (hopefully) successful treatments like SNG 001 - I believe this will be rolled out at the very earliest opportunity
Good evening Really exciting and positive times investing in CV-19 treatment companies. Good day today trading some of the big movers but have cashed out tonight apart from SNG as I fancy that to keep moving upwards in the morning - which other companies should I be looking at regarding addressing CV-19 testing and treatment challenges? Thoughts and insights appreciated Rgds
You seem to have lost your Rose enthusiasm!
How do you know?
I watched the video again last night and noticed a very noticeable wince from MI when the interviewer floated the fact that Sefton had been appointed at the request of 'leading shareholder(s). I wonder who the shareholder was to at last initiate the appointments and board changes - I would imagine an institution who perhaps has the corporate weight and city contacts to drive such change? MI's casual demeanour in his most recent interviews is in marked contrast to this interview - suited and booted this time around...
Our CEO's latest venture - Legology Ltd - doesn't strike me that our interests are being best represented here.
Where are you Rose Board of Directors?
Company indications (many...!.) that we would be drilling in Q1 and nothing what so ever with regards to updates on anything!!!!
I am getting tied of banal Rose PR twitter noise - almost daily - which I am assuming is an attempt at 'communication' but it is vague and increasingly unconvincing!!!!
Or maybe a sky diving trip....?
What is occurring...?